Results 91 to 100 of about 87,967 (330)

PHARMACOLOGY OF PHOSPHODIESTERASE‐5 INHIBITORS

International Journal of Clinical Practice, 2002
SUMMARYThe clinical properties (efficacy and safety profile) of a medicine are related not only to its mode of action, but also to its selectivity for its target (usually a receptor or enzyme) and are also influenced by its pharmacokinetic properties (absorption, distribution, metabolism and elimination).
J D, Corbin, S H, Francis
openaire   +2 more sources

Pharmacokinetics, Bioequivalence, and Safety Studies of Crisaborole Ointment in Healthy Chinese Subjects

Clinical Pharmacology in Drug Development, EarlyView.
Abstract The aim of this study was to evaluate the bioequivalence and safety of a single application of crisaborole ointment to test formulation and reference formulation in healthy subjects under fasting conditions. A total of 32 subjects were included and divided into 2 groups (test‐reference; reference‐test).
Yanchao Wang, Xiaofei Zhao, Taixin Wang, Luning Xiong, Xiujuan Liu, Jing Pan, Wen Yin, Chao Zhang, Jining Dong, Kexin Zhao   +9 more
wiley   +1 more source

5-Hydroxy-3-(4-hydroxyphenyl)-8,8-dimethyl-6- (3-methylbut-2-enyl)pyrano[2,3-h]chromen-4-one [PDF]

, 2018
Natural and semi-synthetic compounds are being studied as novel phosphodiesterase 5 (PDE5) inhibitors for the treatment of erectile dysfunction, pulmonary hypertension, and lower urinary symptoms.
Ongaro, Alberto, Ribaudo, Giovanni, Zagotto, Giuseppe   +2 more
core   +1 more source

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley   +1 more source

Phosphodiesterase-5 inhibitors: Raynaud's and beyond

Indian Journal of Rheumatology, 2017
Phosphodiesterases (PDE) are a group of ubiquitously present enzymes involved in regulation of various cellular pathways. PDE5 acts to metabolize cyclic guanosine monophosphate (GMP).
Sanat Phatak, Sajal Ajmani, Vikas Agarwal, Durga Prasanna Misra   +3 more
doaj  

Myocardial inflammation is associated with impaired mitochondrial oxidative capacity in ischaemic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1246-1255, April 2025.
Abstract Aims Myocardial inflammation and impaired mitochondrial oxidative capacity are hallmarks of heart failure (HF) pathophysiology. The extent of myocardial inflammation in patients suffering from ischaemic cardiomyopathy (ICM) or dilated cardiomyopathy (DCM) and its association with mitochondrial energy metabolism are unknown.
Julius Borger, Elric Zweck, Constanze Moos, Patrick Horn, Fabian Voß, Heinz‐Peter Schultheiss, Jacob Eifer Møller, Udo Boeken, Hug Aubin, Artur Lichtenberg, Malte Kelm, Michael Roden, Amin Polzin, Ralf Westenfeld, Julia Szendroedi, Daniel Scheiber   +15 more
wiley   +1 more source

Effects of cyclic adenosine 3,5-monophosphate on photoreceptor disc shedding and retinomotor movement. Inhibition of rod shedding and stimulation of cone elongation. [PDF]

, 1982
As a test of the hypothesis that cyclic nucleotides play a role in the regulation of retinomotor movements and disc shedding in the photoreceptor-pigment epithelial complex, we have used an in vitro eyecup preparation that sustains both disc shedding and
Besharse, J, BURNSIDE, Beth, Dunis, D
core   +1 more source

Cardiac hypertrophy is inhibited by a local pool of cAMP regulated by phosphodiesterase 2 [PDF]

, 2015
Rationale: Chronic elevation of 3'-5'-cyclic adenosine monophosphate (cAMP) levels has been associated with cardiac remodelling and cardiac hypertrophy.
Aronsen, Jan M., Baillie, George S., Corsetti, Veronica, Dodoni, Giuliano, Fields, Laura A., Furlan, Leonardo, Gesellchen, Frank, Graham, Delyth, Hamilton, Graham M., Jiang, He, Krall, Judith, Lefkimmiatis, Konstantinos, Livie, Craig, Mancuso, Luisa, Movsesian, Matthew, Nicklin, Stuart A., Sin, Yuan Yan, Sjaastad, Ivar, Stangherlin, Alessandra, Surdo, Nicoletta C., Szabo-Fresnais, Nicolas, Terrin, Anna, Vandeput, Fabrice, Zaccolo, Manuela, Zoccarato, Anna   +24 more
core   +1 more source

SPARCL1 and NT‐proBNP as biomarkers of right ventricular‐to‐pulmonary artery uncoupling in pulmonary hypertension

ESC Heart Failure, Volume 12, Issue 2, Page 1416-1426, April 2025.
Abstract Aims SPARCL1 was recently identified as a biomarker of right ventricular (RV) maladaptation in patients with pulmonary hypertension (PH), and N‐terminal pro‐brain natriuretic protein (NT‐proBNP) is an established biomarker of RV failure in PH. The present study investigated whether NT‐proBNP and SPARCL1 concentrations are associated with load ...
Oliver Dörr, Stanislav Keranov, Paulina van Wickern, Holger Nef, Christian Hamm, Pascal Bauer, Christian Troidl, Samuel Sossalla, Sandra Voss, Christoph Liebetrau, Manuel J. Richter, Henning Gall, Werner Seeger, Ardeschir Ghofrani, Athiththan Yogeswaran, Khodr Tello   +15 more
wiley   +1 more source

Tonic and phasic nitric oxide signals in hippocampal long-term potentiation [PDF]

, 2006
Nitric oxide ( NO) participates in long-term potentiation (LTP) and other forms of synaptic plasticity in many different brain areas but where it comes from and how it acts remain controversial.
Garthwaite, J, Hopper, RA
core   +1 more source